tradingkey.logo

Tempus AI Inc

TEM
查看詳細走勢圖
54.910USD
+2.470+4.71%
收盤 02/06, 16:00美東報價延遲15分鐘
9.76B總市值
虧損本益比TTM

Tempus AI Inc

54.910
+2.470+4.71%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+4.71%

5天

-8.21%

1月

-21.04%

6月

-1.12%

今年開始到現在

-7.01%

1年

-15.51%

查看詳細走勢圖

TradingKey Tempus AI Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Tempus AI Inc當前公司基本面數據相對健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名65/392位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為87.42。中期看,股價處於下降通道。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Tempus AI Inc評分

相關信息

行業排名
65 / 392
全市場排名
185 / 4521
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Tempus AI Inc亮點

亮點風險
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
業績高增長
公司營業收入穩步增長,連續3年增長116.24%
利潤高增長
公司淨利潤處於行業前列,最新年度總收入693.40M美元
估值低估
公司最新PE估值-188.90,處於3年歷史低位
機構加倉
最新機構持股96.30M股,環比增加4.83%
約翰·胡斯曼持倉
明星投資者約翰·胡斯曼持倉,最新持倉42.00K股

分析師目標

基於 17 分析師
買入
評級
87.419
目標均價
+66.70%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Tempus AI Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Tempus AI Inc簡介

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
公司代碼TEM
公司Tempus AI Inc
CEOLefkofsky (Eric P)
網址https://investors.tempus.com/
KeyAI